NovaCath | Integrated IV Catheter System

Only NovaCath has the safety and stability you’ve been asking for in an integrated, easy-to-use catheter system

The NovaCath PIVC integrates advanced catheter stabilization to help you cost-effectively comply with nursing guidelines while maximizing patient outcomes.

NovaCath is the first and only peripheral IV catheter designed to reduce catheter movements in all directions with an advanced stabilization frame that absorbs forces away from the insertion site. By integrating closed extension set technology, NovaCath also helps you simplify and standardize the IV catheter setup process, while reducing the risk of exposure to blood-borne pathogens.

Nursing guidelines recommend the use of stabilization devices on all peripheral IV catheters to minimize the risk of complications.1

Movement of an IV catheter relative to the vessel wall has been shown to lead to catheter complications, including infiltration, phlebitis, dislodgement, and mechanical failure, requiring catheters to be restarted before therapy is complete.2 As a result, maximizing catheter stabilization may help your efforts to minimize catheter movement and associated complications.

Cost-Effective Compliance

Built-in stabilization frame lets you eliminate add-on
securement devices

Help Minimize Complications

Stabilization can help reduce complications and extend
dwell times2

Reduce Exposure
to Blood

Closed system minimizes exposure during and
after insertion

Simplify PIVC Setup and Insertion

Integrated components help you standardize and expedite
setup protocols


Maximize patient and clinician safety with IV catheter technology featuring advanced stabilization, passive needle encapsulation, and integrated IV tubing with closed system blood control.

Request More Information


1 Infusion Nurses Society. Infusion nursing standards of practice. J Infus Nurs. 2011; 34 (suppl 1): S1-S110.
2 Rickard CM, Webster J, Wallis MC. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomized controlled equivalence trial. Lancet. 2012; 380 (9847): 1066-1074.